Adjupanrix Pandemic Influenza Vaccine (split virion inactivated AS03 adjuvanted) Singapore - English - HSA (Health Sciences Authority)

adjupanrix pandemic influenza vaccine (split virion inactivated as03 adjuvanted)

glaxosmithkline pte ltd - split influenza virus, inactivated, containing antigen eqv a/vietnam/1194/2004 (h5n1) - injection, emulsion - split influenza virus, inactivated, containing antigen eqv a/vietnam/1194/2004 (h5n1) 3.75 µg haemagglutinin/dose

Arepanrix European Union - English - EMA (European Medicines Agency)

arepanrix

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance

PANDEMRIX H1N1 pandemic influenza vaccine split virion inactivated AS03 adjuvanted 0.5 mL dose Australia - English - Department of Health (Therapeutic Goods Administration)

pandemrix h1n1 pandemic influenza vaccine split virion inactivated as03 adjuvanted 0.5 ml dose

glaxosmithkline australia pty ltd - influenza virus haemagglutinin -

Intanza New Zealand - English - Medsafe (Medicines Safety Authority)

intanza

sanofi-aventis new zealand limited - influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing); influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing); influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) - suspension for injection - 15 mcg - active: influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing) influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing) influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection

Intanza New Zealand - English - Medsafe (Medicines Safety Authority)

intanza

sanofi-aventis new zealand limited - influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a); influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a); influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) - suspension for injection - 9 mcg - active: influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a) influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a) influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection - intanza 9mcg is indicated for prophylaxis of influenza in adults from 18 to 59 years of age. the use of intanza 9mcg in new zealand should be based on the ministry of health recommendations for influenza vaccination as published in the current new zealand immunisation handbook.

Enzira vaccine suspension for injection 0.5ml pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

enzira vaccine suspension for injection 0.5ml pre-filled syringes

pfizer ltd - influenza virus split virion - suspension for injection

Intanza 15microgram strain vaccine suspension for injection 0.1ml pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

intanza 15microgram strain vaccine suspension for injection 0.1ml pre-filled syringes

sanofi pasteur msd ltd - influenza virus split virion - suspension for injection

Fluarix Tetra vaccine suspension for injection 0.5ml pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

fluarix tetra vaccine suspension for injection 0.5ml pre-filled syringes

glaxosmithkline uk ltd - influenza virus split virion - suspension for injection

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics European Union - English - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

Vepacel European Union - English - EMA (European Medicines Agency)

vepacel

ology bioservices ireland ltd - influenza virus (whole virion, inactivated), containing antigen of: a/vietnam/1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influenza vaccines - active immunisation against h5n1 subtype of influenza a virus. this indication is based on immunogenicity data from subjects from the age of 6 months onwards following administration of two doses of vaccine prepared with h5n1 subtype strains. vepacel should be used in accordance with official guidance.,